JP2010090149A5 - - Google Patents

Download PDF

Info

Publication number
JP2010090149A5
JP2010090149A5 JP2009279362A JP2009279362A JP2010090149A5 JP 2010090149 A5 JP2010090149 A5 JP 2010090149A5 JP 2009279362 A JP2009279362 A JP 2009279362A JP 2009279362 A JP2009279362 A JP 2009279362A JP 2010090149 A5 JP2010090149 A5 JP 2010090149A5
Authority
JP
Japan
Prior art keywords
cooh
following formula
carbon atoms
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009279362A
Other languages
English (en)
Japanese (ja)
Other versions
JP5603593B2 (ja
JP2010090149A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010090149A publication Critical patent/JP2010090149A/ja
Publication of JP2010090149A5 publication Critical patent/JP2010090149A5/ja
Application granted granted Critical
Publication of JP5603593B2 publication Critical patent/JP5603593B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2009279362A 2002-01-07 2009-12-09 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン Expired - Fee Related JP5603593B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34649202P 2002-01-07 2002-01-07
US60/346,492 2002-01-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003557380A Division JP4571408B2 (ja) 2002-01-07 2003-01-07 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013172071A Division JP2013237701A (ja) 2002-01-07 2013-08-22 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン

Publications (3)

Publication Number Publication Date
JP2010090149A JP2010090149A (ja) 2010-04-22
JP2010090149A5 true JP2010090149A5 (US06780888-20040824-C00057.png) 2012-03-01
JP5603593B2 JP5603593B2 (ja) 2014-10-08

Family

ID=23359639

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003557380A Expired - Lifetime JP4571408B2 (ja) 2002-01-07 2003-01-07 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン
JP2009279362A Expired - Fee Related JP5603593B2 (ja) 2002-01-07 2009-12-09 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン
JP2013172071A Pending JP2013237701A (ja) 2002-01-07 2013-08-22 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン
JP2015051753A Pending JP2015120745A (ja) 2002-01-07 2015-03-16 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003557380A Expired - Lifetime JP4571408B2 (ja) 2002-01-07 2003-01-07 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013172071A Pending JP2013237701A (ja) 2002-01-07 2013-08-22 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン
JP2015051753A Pending JP2015120745A (ja) 2002-01-07 2015-03-16 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン

Country Status (6)

Country Link
US (4) US6911471B2 (US06780888-20040824-C00057.png)
EP (3) EP2420229A1 (US06780888-20040824-C00057.png)
JP (4) JP4571408B2 (US06780888-20040824-C00057.png)
AU (1) AU2003207455B2 (US06780888-20040824-C00057.png)
CA (1) CA2472633C (US06780888-20040824-C00057.png)
WO (1) WO2003057012A2 (US06780888-20040824-C00057.png)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2420229A1 (en) * 2002-01-07 2012-02-22 Board Of Regents, University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
AU2011204901B2 (en) * 2004-07-16 2013-09-12 Board Of Regents, The University Of Texas System Compounds and methods for treatment of cancer
TW201440760A (zh) * 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
WO2007027344A2 (en) * 2005-07-29 2007-03-08 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
JP5202332B2 (ja) 2006-01-13 2013-06-05 ザ テキサス エー アンド エム ユニバーシティ システム がんの治療のための化合物および方法
TW200829261A (en) 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
CN101595115B (zh) * 2006-11-01 2012-07-18 新南部创新有限公司 有机-氧化砷化合物及其用途
ES2392737T3 (es) * 2007-11-02 2012-12-13 Ziopharm Oncology, Inc. Terapia combinada con compuestos arsenicales orgánicos
CN101874034A (zh) * 2007-12-12 2010-10-27 Zio医药肿瘤学公司 用于治疗癌症的化合物和方法
BRPI0912175A2 (pt) * 2008-05-28 2015-10-06 Basf Se métodos para diagnosticar indução de enzima do fígado, para determinar se um composto é capaz de induzir indução de enzima do fígado em um indivíduo, e para identificar uma substância para tratar indução de enzima do fígado
DK2321012T3 (en) 2008-08-20 2018-12-03 Solasia Pharma K K ORGANIC RELATIONS AND PROCEDURES FOR TREATING CANCER
WO2011133475A2 (en) * 2010-04-19 2011-10-27 Sri International Compositions and method for the treatment of multiple myeloma
US20160304546A1 (en) * 2013-12-05 2016-10-20 Solasia Pharma K.K. Compounds and methods for the treatment of cancer
CN112941027B (zh) * 2021-03-19 2021-11-02 苏州大学 二甲基亚胂酸致人角质形成细胞恶性转化细胞株及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2349729A (en) * 1940-08-24 1944-05-23 Parke Davis & Co Therapeutic arsenic preparation
US2701812A (en) * 1951-06-26 1955-02-08 Dainippon Pharmaceutical Co Diarylarsenious acid derivatives and the preparation thereof
DE3229565A1 (de) * 1982-08-07 1984-02-16 Etschenberg, Eugen, Dr., 5000 Köln Arsenhaltige nucleoside
FR2640269B1 (fr) * 1988-12-13 1991-03-15 Maes Ludo Composes organometalliques, leurs modes de preparation et compositions pharmaceutiques les contenant
AU751932B2 (en) * 1997-10-15 2002-08-29 Polarx Biopharmaceuticals, Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
PT1964557E (pt) * 1997-11-10 2013-02-20 Sloan Kettering Inst Cancer Processo para a produção de formulações de trióxido de arsénio
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) * 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
AUPQ296799A0 (en) 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
AU5391901A (en) * 2000-04-26 2001-11-07 Univ Oregon Health Sciences Administration of a thiol-based chemoprotectant compound
AUPR379801A0 (en) 2001-03-19 2001-04-12 Unisearch Limited Use of a substantially cell membrane impermeable compound for treating arthritis
AUPR598901A0 (en) 2001-06-28 2001-07-19 Unisearch Limited Inhibition of angiogenesis by targeting protein tyrosine phosphatases
WO2003003956A1 (en) 2001-07-06 2003-01-16 Cochlear Limited Configuration of implanted devices
EP2420229A1 (en) * 2002-01-07 2012-02-22 Board Of Regents, University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
CA2504935C (en) 2002-11-07 2012-04-10 Unisearch Limited Induction of the mitochondrial permeability transition
TW201440760A (zh) 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
CN101595115B (zh) 2006-11-01 2012-07-18 新南部创新有限公司 有机-氧化砷化合物及其用途

Similar Documents

Publication Publication Date Title
JP2010090149A5 (US06780888-20040824-C00057.png)
JP2010077141A5 (US06780888-20040824-C00057.png)
JP2009530398A5 (US06780888-20040824-C00057.png)
JP2013519632A5 (US06780888-20040824-C00057.png)
JP2010523476A5 (US06780888-20040824-C00057.png)
JP2016534063A5 (US06780888-20040824-C00057.png)
JP2018524304A5 (US06780888-20040824-C00057.png)
JP2012506896A5 (US06780888-20040824-C00057.png)
JP2009524675A5 (US06780888-20040824-C00057.png)
JP2008543854A5 (US06780888-20040824-C00057.png)
JP2008509953A5 (US06780888-20040824-C00057.png)
JP2008546770A5 (US06780888-20040824-C00057.png)
JP2009502777A5 (US06780888-20040824-C00057.png)
JP2012502037A5 (US06780888-20040824-C00057.png)
JP2012512907A5 (US06780888-20040824-C00057.png)
JP2013518107A5 (US06780888-20040824-C00057.png)
JP2007302689A5 (US06780888-20040824-C00057.png)
JP2010504343A5 (US06780888-20040824-C00057.png)
RU2013119966A (ru) Композиция, улучшающая растворимость плохорастворимого лекарственного препарата
JP2009501234A5 (US06780888-20040824-C00057.png)
JP2011527345A5 (US06780888-20040824-C00057.png)
JP2012513416A5 (US06780888-20040824-C00057.png)
JP2011046708A5 (US06780888-20040824-C00057.png)
JP2008542386A5 (US06780888-20040824-C00057.png)
JP2014505017A5 (US06780888-20040824-C00057.png)